Morten Hvidtfeldt

Morten Hvidtfeldt

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2013 in BMJ Open
Verified
Journal Article
Open access
PDF file
RSRikke Sørensen
Rikke Sørensen
GGGunnar Gislason
Gunnar Gislason
CTChristian Torp-Pedersen
Christian Torp-Pedersen
JOJonas Bjerring Olesen
Jonas Bjerring Olesen
EFEmil L Fosbøl
Emil L Fosbøl
MHMorten Lock Hansen
Morten Lock Hansen
Objective Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. Design Pharmacoepidemiological cohort study. Methods/settings From nationwide registers, we identified patients with an in-hospital or outpatient-clinic AF diagnosis who claimed a prescription of dabigatran 110 or 150 mg, or vitamin K antagonist (VKA), between 22 August and 31 December 2011. HRs of thromboembolic events (ischaemic stroke, transitory ischaemic attack and peripheral artery embolism) and bleedings were estimated using Cox regression analyses in all patients and stratified by previous VKA use. Results Overall, 1612 (3.1%) and 1114 (2.1%) patients claimed a prescription of dabigatran 110 and 150 mg, and 49640 (94.8%) of VKA. Patients treated with dabigatran 150 mg were younger with less comorbidity than those treated with dabigatran 110 mg and VKA, as were VKA naïve patients compared with previous VKA users. Recommendations set by the European Medicine Agency (EMA) for dabigatran were met in 90.3% and 55.5% of patients treated with 110 and 150 mg. Patients treated with 150 mg dabigatran, who did not fulfil the recommendations by EMA, were >80 years, patients with liver or kidney disease, patients with previous bleeding. Compared with VKA, the thromboembolic risk associated with dabigatran 110 and 150 mg was HR 3.52 (1.40 to 8.84) and 5.79 (1.81 to 18.56) in previous VKA users, and HR 0.95(0.47 to 1.91) and 1.14(0.60 to 2.16) in VKA naïve patients. Bleeding risk was increased in previous VKA users receiving dabigatran 110 mg, but not in patients with 150 mg dabigatran, nor in the VKA naïve users. Conclusions Deviations from the recommended use of dabigatran were frequent among patients treated with 150 mg. With cautious interpretation, dabigatran use in VKA naïve patients seems safe. Increased risk of thromboembolism and bleeding with dabigatran among previous VKA users was unexpected and may reflect patient selection and ‘drug switching’ practices.

3 November 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DKDeniz Karasoy
Deniz Karasoy
GGGunnar Hilmar Gislason
Gunnar Hilmar Gislason
JHJim Hansen
Jim Hansen
AJArne Johannessen
Arne Johannessen
LKLars Køber
Lars Køber
MHMorten Lock Hansen
Morten Lock Hansen
To investigate the long-term risk of thromboembolism and serious bleeding associated with oral anticoagulation (OAC) therapy beyond 3 months after radiofrequency ablation (RFA) of atrial fibrillation (AF). Linking Danish administrative registries, 4050 patients undergoing first-time RFA (2000–11) were identified. Risk of thromboembolism and serious bleeding according to OAC therapy were analysed by incidence rates (presented per 100 person-years) and Cox proportional-hazard models. The median age was 59.5 years (interquartile range, IQR: 52.8–65.2); 26.5% were females. During a median follow-up of 3.4 years (IQR: 2.0–5.6), 71 (1.8%) thromboembolism cases were identified, where incidence rates with and without OAC were 0.56 (0.40–0.78)95%CI and 0.64 (0.46–0.89)95%CI, respectively. Oral anticoagulation discontinuation remained insignificant [hazard ratio 1.42(0.86–2.35)95%CI] in multivariable analysis. Beyond 3 months after RFA 87 (2.1%) serious bleedings occurred; incidence rates with and without OAC were 0.99 (0.77–1.27)95%CI and 0.44 (0.29–0.65)95%CI, respectively. Oral anticoagulation therapy was significantly associated with serious bleeding risk [hazard ratio 2.05(1.25–3.35)95%CI]. In an age- and gender-matched cohort (1 : 4) of 15 848 non-ablated AF patients receiving rhythm-control therapy, thromboembolic rates with and without OAC were 1.34 (1.21–1.49)95%CI and 2.14 (1.98–2.30)95%CI, respectively. Adjusted incidence rate ratio was 0.53 (0.43–0.65)95%CI favouring RFA cohort. Thromboembolic risk beyond 3 months after RFA was relatively low compared with a matched non-ablated AF cohort. With cautious interpretation due to low number of events, serious bleeding risk associated with OAC seems to outweigh the benefits of thromboembolic risk reduction. Randomized studies are warranted to test our results.

20 March 2014 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Closed access
PDF file
CSC. Siebenmann
C. Siebenmann
PRP. Rasmussen
P. Rasmussen
HSH. Sørensen
H. Sørensen
MZM. Zaar
M. Zaar
MHMorten Hvidtfeldt
Morten Hvidtfeldt
CLCarsten Lundby
Carsten Lundby

27 October 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
LFLaurits Frøssing
Laurits Frøssing
DKDitte K. Klein
Ditte K. Klein
MHMorten Hvidtfeldt
Morten Hvidtfeldt
NONicolai Obling
Nicolai Obling
GTGunilla Telg
Gunilla Telg
CPCeleste Porsbjerg
Celeste Porsbjerg
Background: Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population.Methods: Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×109 cells·L−1and 3% respectively), total IgE (≥150 U·mL−1), and fractional exhaled nitric oxide (≥25 ppb).Results: Patients with mild-to-moderate asthma were younger (41versus49 years, p<0.001), had lower body mass index (25.9versus28.0 kg·m−2, p=0.002) and less atopy (47%versus58%, p=0.05), higher forced expiratory volume in 1 s (3.2versus2.8 L, p<0.001) and forced vital capacity (4.3versus3.9 L, p<0.001) compared with patients with severe asthma, who had higher blood (0.22×109versus0.17×109 cells·L−1, p=0.01) and sputum (3.0%versus1.5%, p=0.01) eosinophils. Co-expression of all T2 biomarkers was a particular characteristic of severe asthma (p<0.001). In patients with eosinophilia, sputum eosinophilia without blood eosinophilia was present in 45% of patients with mild-to-moderate asthma and 35% with severe asthma.Conclusion: Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.

12 March 2014 in Clinical Physiology and Functional Imaging
Verified
Journal Article
Closed access
PDF file
HSHenrik Sørensen
Henrik Sørensen
PRPeter Rasmussen
Peter Rasmussen
CSChristoph Siebenmann
Christoph Siebenmann
MZMorten Zaar
Morten Zaar
MHMorten Hvidtfeldt
Morten Hvidtfeldt
CLCarsten Lundby
Carsten Lundby

2 March 2022 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
DKDitte K. Klein
Ditte K. Klein
ASAlexander Silberbrandt
Alexander Silberbrandt
LFLaurits Frøssing
Laurits Frøssing
MHMorten Hvidtfeldt
Morten Hvidtfeldt
ABAnna von Bülow
Anna von Bülow
CPCeleste Porsbjerg
Celeste Porsbjerg
Introduction: Severe eosinophilic asthma is characterised by frequent exacerbations and a relative insensitivity to steroids. Experimentally, smoking may induce eosinophilic airway inflammation, but the impact in patients with severe asthma is not clear.Objective: To investigate the association between smoking exposure in patients with severe asthma, and eosinophilic inflammation and activation, as well as airway autoimmunity and steroid responsiveness.Methods: Patients with severe asthma according to European Respiratory Society/American Thoracic Society criteria were assessed with sputum samples, analysed by cell differential count, and for the presence of free eosinophil granules (FEGs), autoantibodies against eosinophil peroxidase (EPX) and macrophage receptor with collagenous structure (MARCO). A subgroup of patients with eosinophilic airway inflammation was re-assessed after a 2-week course of prednisolone.Results: 132 severe asthmatics were included in the study. 39 (29.5%) patients had ≥10 pack-years of smoking history: 36 (27.3%) were former smokers and three (2.3%) current smokers; and 93 (70.5%) had <10 pack-years exposure. Eosinophilic airway inflammation was more prevalent among patients with ≥10 pack-years (66.7%), compared to patients with <10 pack-years (38.7%, p=0.03), as was the level of FEGs (p=0.001) and both anti-EPX and anti-MARCO (p<0.05 and p<0.0001, respectively). Omitting current smokers did not affect these associations. Furthermore, prednisolone reduced, but did not normalise, sputum eosinophils in patients with a ≥10 pack-year smoking history.Conclusion: In patients with severe asthma, a former smoking history is associated with eosinophilic airway inflammation and activation and relative insensitivity to steroids, as well as airway autoimmunity.